Published in Prog Drug Res on January 01, 2011
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J Natl Cancer Inst (2013) 0.91
FANSe: an accurate algorithm for quantitative mapping of large scale sequencing reads. Nucleic Acids Res (2012) 0.87
Identification of regulatory SNPs associated with genetic modifications in lung adenocarcinoma. BMC Res Notes (2015) 0.85
PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. Epigenetics (2012) 0.82
Targeting deregulated epigenetic control in cancer. J Cell Physiol (2013) 0.82
Epigenetic activities of flavonoids in the prevention and treatment of cancer. Clin Epigenetics (2015) 0.78
Hierarchical clustering of breast cancer methylomes revealed differentially methylated and expressed breast cancer genes. PLoS One (2015) 0.77
Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis. J Cell Mol Med (2014) 0.77
Down-Regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells. J Biol Chem (2017) 0.75
Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma. BMC Cancer (2016) 0.75
Cancer: we should not forget the past. J Cancer (2015) 0.75
1,4-benzoquinone-induced STAT-3 hypomethylation in AHH-1 cells: Role of oxidative stress. Toxicol Rep (2015) 0.75
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell (1992) 27.80
The role of chromatin during transcription. Cell (2007) 26.48
DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell (1999) 25.75
Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature (2009) 24.41
A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol (2008) 21.72
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet (2009) 18.90
The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science (2009) 18.82
DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 18.08
High sensitivity mapping of methylated cytosines. Nucleic Acids Res (1994) 16.62
Eukaryotic cytosine methyltransferases. Annu Rev Biochem (2005) 15.45
DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet (2008) 15.45
Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet (2005) 15.37
Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature (2000) 14.91
CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature (2000) 12.97
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet (2009) 12.08
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev (2002) 10.54
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet (2006) 10.47
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res (1997) 8.88
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev (2004) 8.66
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
The colorful history of active DNA demethylation. Cell (2008) 8.50
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol (2008) 7.95
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature (2004) 7.57
The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol (2001) 7.20
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat Rev Genet (2008) 5.67
DNA methylation of retrotransposon genes is regulated by Piwi family members MILI and MIWI2 in murine fetal testes. Genes Dev (2008) 5.58
Mapping global histone acetylation patterns to gene expression. Cell (2004) 5.57
Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell (2008) 5.40
X chromosome dosage compensation: how mammals keep the balance. Annu Rev Genet (2008) 5.18
An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). Genome Res (2008) 4.84
CpG islands--'a rough guide'. FEBS Lett (2009) 4.55
Suppression of intestinal neoplasia by DNA hypomethylation. Cell (1995) 4.16
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet (2006) 3.89
Relaxation of imprinted genes in human cancer. Nature (1993) 3.86
MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res (2006) 3.66
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn (2007) 3.56
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet (2004) 3.33
Sin meets NuRD and other tails of repression. Cell (1999) 3.31
Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet (1999) 3.26
Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet (2000) 3.24
Epigenomics: beyond CpG islands. Nat Rev Genet (2004) 3.21
Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. Nat Rev Mol Cell Biol (2009) 3.12
High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. Genome Res (2009) 3.08
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem (2006) 2.70
Meiotic and epigenetic defects in Dnmt3L-knockout mouse spermatogenesis. Proc Natl Acad Sci U S A (2005) 2.56
Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res (2002) 2.56
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res (2008) 2.28
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23
CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene (1995) 2.23
Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res (2006) 2.22
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res (1999) 2.19
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst (2005) 2.08
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica (2005) 1.93
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res (2009) 1.80
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene (1999) 1.80
Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res (1997) 1.79
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A (2006) 1.75
Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene (1998) 1.74
Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res (1995) 1.68
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Methylation dynamics of repetitive DNA elements in the mouse germ cell lineage. Genomics (2003) 1.58
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol (2009) 1.58
Genome-wide profiling of promoter methylation in human. Oncogene (2006) 1.55
Loss of imprinting and cancer. J Pathol (2007) 1.52
G9a histone methyltransferase contributes to imprinting in the mouse placenta. Mol Cell Biol (2007) 1.51
Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol (2005) 1.43
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet (2011) 2.45
Restriction landmark genome scanning. Methods (2002) 2.20
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet (2003) 2.18
Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med (2009) 2.08
Lung cancer epigenetics and genetics. Int J Cancer (2008) 2.08
Regulation of DNA methylation of Rasgrf1. Nat Genet (2001) 2.06
Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol (2003) 2.04
SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A (2003) 2.01
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res (2013) 1.86
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood (2007) 1.82
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A (2006) 1.75
Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst (2006) 1.72
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome. Hum Mol Genet (2007) 1.68
Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res (2009) 1.67
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene (2003) 1.64
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica (2011) 1.63
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest (2004) 1.58
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer (2006) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem (2004) 1.54
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res (2004) 1.52
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res (2008) 1.49
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res (2006) 1.49
HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A (2002) 1.43
Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res (2008) 1.43
Tissue specific DNA methylation of CpG islands in normal human adult somatic tissues distinguishes neural from non-neural tissues. Epigenetics (2010) 1.41
Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol (2006) 1.40
DNA motifs associated with aberrant CpG island methylation. Genomics (2006) 1.40
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol (2005) 1.39
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2009) 1.39
Unraveling the epigenetic code of cancer for therapy. Trends Genet (2007) 1.35
Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma. J Biol Chem (2002) 1.35
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol (2013) 1.34
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34
miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res (2012) 1.33
Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene (2002) 1.32
CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet (2007) 1.28
Toward a human epigenome. Nat Genet (2006) 1.28
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood (2009) 1.25
Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med (2013) 1.23
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene (2003) 1.23
The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene (2002) 1.22
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. Genomics (2004) 1.20
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood (2010) 1.19
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. Proc Natl Acad Sci U S A (2003) 1.19
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res (2012) 1.18
Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med (Berl) (2006) 1.16
Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genomics (2008) 1.15
Tagmentation-based whole-genome bisulfite sequencing. Nat Protoc (2013) 1.14
Cancer chemoprevention by targeting the epigenome. Curr Drug Targets (2011) 1.13
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood (2008) 1.12
Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood (2011) 1.12
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov (2013) 1.11
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest (2012) 1.11
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10
Calcification of myocardial necrosis is common in mice. Virchows Arch (2005) 1.08
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet (2013) 1.08
HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One (2010) 1.08
Structural characterization of Rasgrf1 and a novel linked imprinted locus. Gene (2002) 1.07
Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics (2007) 1.07
Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene (2004) 1.06